Myriad Genetics, Inc.’s (MYGN) share price has entered into oversold territory with a stochastic value of 17.8110. The Zacks Consensus Estimate on the company’s earnings for year ending June 2013 increased by 4 cents over the past week to $1.58 per share. Myriad Genetics, Inc. is a Zacks Rank #1 (“Strong Buy”) company.
MYRIAD GENETICS (MYGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment